Mixed
Combining SGLT-2 inhibitors with appetite-suppressing agents (like GLP-1 receptor agonists or phentermine) overcomes the counter-regulatory increase in food intake, resulting in significantly greater weight loss (3–7.3 kg) than either drug alone.
If SGLT-2 inhibitors alone aren't moving the needle enough, combining them with an appetite suppressant (like a GLP-1 agonist or phentermine) is a proven strategy. This combo tackles weight loss from two angles: peeing out calories and feeling less hungry. Clinical trials show this can lead to 3–7 kg of weight loss, significantly more than either drug used by itself.
Co-administration of SGLT2 inhibitors together with agents that reduce food intake target complementary mechanisms and represent an effective weight loss therapy.
Why this rating
Supported by specific clinical trials (DURATION-8, Lundkvist et al., Hollander et al.) cited in the text.
Source
Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
Maria J. Pereira et al. · Drugs · 2019
DOI 10.1007/s40265-019-1057-0
Related findings · Mixed
- Bariatric surgery (VSG and RYGB) is the most effective and sustainable treatment for obesity, producing marked and sustained weight loss that non-surgical interventions cannot match.Strong
- Severely protein-deficient diets (2–3% energy) induce lean body mass loss and metabolic imbalance, whereas adequate protein intake (0.66 g/kg/d minimum) is a prerequisite for maintaining muscle, bone, and physiological function.Strong
- For patients with Class III obesity (BMI >39.9 kg/m2), metabolic bariatric surgery (MBS) is significantly more effective than any currently approved medication, with BilioPancreatic Diversion (BPD) showing the highest estimated weight loss.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →